Germline polymorphisms as biomarkers of tumor response in colorectal cancer patients treated with anti-EGFR monoclonal antibodies: a systematic review and meta-analysis

E. K. Morgen, H. J. Lenz, D. J. Jonker, D. Tu, G. Milano, F. Graziano, J. Zalcberg, C. S. Karapetis, A. Dobrovic, C. J. O’Callaghan, G. Liu

Research output: Contribution to journalArticleResearchpeer-review

1 Citation (Scopus)

Abstract

Studies of germline polymorphisms as predictors of tumor response to anti-epidermal growth factor receptor (EGFR) monoclonal antibody agents in metastatic colorectal cancer have reported inconsistent results. We performed a systematic review of studies from 1990 to September 2015, followed by random-effects meta-analyses for polymorphisms examined in at least three studies. Of 87 studies, 40 passed the criteria for systematic review and 23 for meta-analysis. The polymorphisms suitable for meta-analysis were CCND1 (rs17852153), COX2 (rs20417), EGF (rs4444903), EGFR (rs712829, rs11543848, 3′UTR CA repeat), FCGR2A (rs1801274), FCGR3A (rs396991), IL8 (rs4073), KRAS (rs61764370) and VEGFA (rs3025039). Meta-analysis yielded nominal significance (at α=0.05) for rs4444903 and rs11543848, but showed no significant results after multiple testing correction; this was unchanged by sensitivity analyses to address subgroups, funnel-plot asymmetries, and study quality. This highlights a tendency for lack of replication in the face of initial positive results, and possibly the unsuitability of relying on tumor response as a surrogate marker in this setting.The Pharmacogenomics Journal advance online publication, 29 November 2016; doi:10.1038/tpj.2016.56.

Original languageEnglish
Pages (from-to)535-542
Number of pages8
JournalPharmacogenomics Journal
Volume17
DOIs
Publication statusPublished - 2017

Cite this